Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Biosimilar Education Campaign Will Need To Be Targeted

This article was originally published in The Pink Sheet Daily

Executive Summary

Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.

You may also be interested in...



Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

Nearly all adverse event reports received by US FDA include brand name of biosimilar, raising questions as to whether suffix on nonproprietary name is necessary for pharmacovigilance.

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

Nearly all adverse event reports received by US FDA include brand name of biosimilar, raising questions as to whether suffix on nonproprietary name is necessary for pharmacovigilance.

Biosimilar Education Needed To Eliminate 'Nocebo' Effect, Pfizer Says

Material to help providers and patients understand scientific issues can inspire more confidence in the products, exec says.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel